⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531090 | 1.00 | — | — | |
| SCHEMBL13359341 | 0.79 | MAN1B1 (0.32) | — | |
| SCHEMBL8344060 | 0.71 | — | — | |
| SCHEMBL3540281 | 0.71 | — | — | |
| SCHEMBL8932418 | 0.71 | — | — | |
| SCHEMBL3540279 | 0.71 | — | — | |
| SCHEMBL9325256 | 0.71 | — | — | |
| SCHEMBL14628805 | 0.71 | PDCD1 (0.32) | — | |
| SCHEMBL8344503 | 0.71 | — | — | |
| SCHEMBL16918281 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100453-B1 | COSMETIC FORMULATION CONTAINING ECTOINE DERIVATIVES, ENZYMES, VITAMINS AND/OR VITAMIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-01-05 | — | — | EP | claimed |
| EP-1100456-B1 | USE OF ECTOINE OR ECTOINE DERIVATIVES IN FORMULATIONS | MERCK PATENT GMBH (DE) | 2002-09-25 | — | — | EP | claimed |
| WO-2023102209-A1 | CLAUDIN INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF CHICAGO (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023286057-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD (IL) | 2023-01-19 | — | — | WO | disclosed |
| EP-3977998-A1 | COMPOSITION FOR TREATING THE EYE | Bitop AG (DE) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-5403845-A | Cognition activators; Alzheimer*s disaease | UNIVERSITY OF TOLEDO (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0630244-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0630244-A4 | MUSCARINIC AGONISTS. | UNIV TOLEDO (US) | 1994-04-07 | — | — | EP | disclosed |
| EP-0320796-B1 | Process for the preparation of phosphoric-acid derivatives and intermediates | BAYER AG (DE) | 1994-03-09 | — | — | EP | disclosed |
| WO-1993003726-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5175166-A | Cognition activators | THE UNIVERSITY OF TOLEDO (US) | 1992-12-29 | — | — | US | disclosed |
| US-5010193-A | Cyclization, oxidation, dehydrogenation, salt formation, desalting, phosphorylating; insecticides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
| EP-0320796-A2 | Process for the preparation of phosphoric-acid derivatives and intermediates | BAYER AG (DE) | 1989-06-21 | — | — | EP | disclosed |
| EP-0309422-A2 | New amidino tricycle derivatives | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-03-29 | — | — | EP | disclosed |